Astronauts who work in the International Space Station (ISS) – the largest modular space station in low Earth orbit that is the cooperative effort of the space agencies of the US, Canada, Japan, Europe and Russia – seem to be more susceptible to infectious diseases while in space.
These astronauts have commonly suffered from skin rashes and respiratory and non-respiratory diseases and to shed more live virus particles such as those from the Epstein-Barr virus, varicella-zoster responsible for shingles, herpes-simplex-1 responsible for sores and cytomegalovirus.Now, Canadian scientists have shown that the expression of mostly protein-coding genes in white blood cells changes rapidly when astronauts reach the ISS. The good news, however, is that most genes returned to their typical pre-flight level of expression within a few weeks to one year after landing, suggesting that Earth-level gravity is required for astronauts’ immune systems to function optimally.
The researchers from the University of Ottawa and Ottawa Hospital have just published their study under the title “‘The transcriptome response of astronaut leukocytes to long missions aboard the International Space Station reveals immune modulation” in the journal Frontiers in Immunology.
What could cause that immune deficit?
These observations suggest that our immune system might be weakened by space travel, but what – the researchers wondered – could cause such an immune deficit?“The expression of many genes related to immune functions rapidly decreases when astronauts reach space, while the opposite happens when they return to Earth after six months aboard the ISS,” said biology Prof. Odette Laneuville of the University of Ottawa whose research was funded by the Canadian Space Agency.The researchers studied gene expression in leukocytes (white blood cells) in a cohort of 14 astronauts including three women and 11 men who resided on board the ISS for between 4.5 and 6.5 months between 2015 and 2019. Leukocytes were isolated from four milliliters of blood drawn from each astronaut at 10-time points – once pre-flight, four times in flight and five times back on Earth.
A total of 15,410 genes were found to be differentially expressed in leukocytes. Among these genes, the researchers identified two clusters, with 247 and 29 genes respectively, which changed their expression in tandem along the studied timeline.Genes in the first cluster were dialed down when reaching space and back up when returning to Earth, while genes in the second followed the opposite pattern. Both clusters mostly consisted of genes that code for proteins, but with a difference: their predominant function was related to immunity for the genes in the first cluster and to cellular structures and functions for the second.These results suggest that when someone travels to space, these changes in gene expression cause a rapid decrease in the strength of their immune system. “A weaker immunity increases the risk of infectious diseases, limiting astronauts’ ability to perform their demanding missions in space. If an infection or an immune-related condition were to evolve to a severe state requiring medical care, astronauts in space would have limited access to care, medication, or evacuation” said Prof. Guy Trudel, a rehabilitation physician and researcher at Ottawa Hospital and the university’s cellular and molecular medicine department. But there is a silver lining to this cloud, as the data showed that most genes in either cluster returned to their pre-flight level of expression within one year after return on Earth and typically much sooner – on average, after a few weeks. These results suggest that returning astronauts run an elevated risk of infection for at least one month after landing back on Earth. The authors don’t yet know how long it takes before immune resistance returns fully to its pre-flight strength, as the length of this period is likely to depend on age, sex, genetic differences and childhood exposure to pathogens.The authors suggested that the change in gene expression of leukocytes under microgravity is triggered by a “fluid shift” in which blood plasma is redistributed from the lower to the upper part of the body, including the lymphatic system. This causes a reduction in plasma volume by between 10% and 15% within the first few days in space. Fluid shift is known to be accompanied by large-scale physiological adaptations, apparently including altered gene expression. “The next question is how to apply our findings to guide the design of countermeasures that will prevent immune suppression while in space in particular for long-duration flight,” said Laneuville. “The health of astronauts while in space, especially during long missions, would benefit from detecting both immune dysfunction and sub-clinical inflammation. Early detection provides opportunities for intervention, with the aim to prevent a progression towards severe symptoms.”